Neuromuscular

Here's some of what is coming soon to NeurologyLive® this week.

Indirect treatment comparisons showed significantly greater or statistically higher improvements in MG-ADL scores with nipocalimab versus other FcRn blockers over 24 weeks.

Denali Therapeutics advances treatment for Hunter syndrome with FDA's priority review of tividenofusp alfa, targeting brain delivery and improved patient outcomes.

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology news headlines you may have missed over the course of June 2025, compiled all into one place by the NeurologyLive® team.

New findings reveal deramiocel's promising long-term benefits for boys with Duchenne muscular dystrophy cardiomyopathy, enhancing cardiac function and muscle performance.

New phase 1 data revealed salanersen's promise to slow neurodegeneration in spinal muscular atrophy, potentially paving the way for future phase 3 trials.

Edgewise Therapeutics reveals promising results for sevasemten, potentially the first approved treatment for Becker muscular dystrophy, enhancing patient outcomes.

Overviewing the major clinical trial readouts in neurology from the first half of 2025, with data that could potentially reshape patient care.

Here's some of what is coming soon to NeurologyLive® this week.

Efgartigimod alfa SC is now approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on pediatric neurology.

Biogen recently launched a pivotal phase 3 trial for omaveloxolone, aiming to explore its safety and efficacy in pediatric patients with Friedreich ataxia.

Marketed as the first drug to target both BLyS and APRIL, Telitacicept may offer a revolutionary treatment option for patients with myasthenia gravis.

Researchers uncover a latent infection model for Creutzfeldt-Jakob disease, revealing insights into its mysterious origins and potential triggers.

New long-term data support ecopipam's safety and sustained efficacy in reducing tics and improving quality of life in pediatric Tourette syndrome.

Here's some of what is coming soon to NeurologyLive® this week.

Avidity Biosciences advances del-brax for FSHD, initiating a pivotal Phase 3 study while exploring accelerated FDA approval pathways.

Daniel Mikol, MD, PhD, chief medical officer at NervGen Pharma, provided clinical perspective on recently announced positive findings from a phase 1b/2a trial testing NVG-291 as a treatment for spinal cord injury.

The neurosurgeon at Northwestern Medicine discussed diagnostic approaches, evolving treatment strategies, and the importance of timely referral in managing peripheral nerve injuries. [WATCH TIME: 3 minutes]

New 5-year findings from the National RLS Opioid Registry presented at SLEEP 2025 highlight the long-term stability and dose trends of low-dose opioid therapy in patients with restless legs syndrome.

Members from Nuvig Therapeutics discussed how NVG-2089 could improve the CIDP treatment landscape by offering IVIG-like efficacy with a better safety and administration profile. [WATCH TIME: 3 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of May 2025, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending June 7, 2025. [WATCH TIME: 4 minutes]

New data reveals RGX-202 gene therapy shows significant improvements in Duchenne muscular dystrophy patients, enhancing disease management and safety.

Phil Lambert, PhD, chief scientific officer at Satellos Bioscience, discusses the rationale and early clinical progress of SAT-3247, a novel regenerative therapy targeting muscle stem cells in Duchenne muscular dystrophy.

AJ201 shows promising safety and efficacy in treating spinal and bulbar muscular atrophy, marking a potential breakthrough for patients.

Josh Bryson, PhD, head of Medical Affairs at Argenx, discussed the safety profile of efgartigimod in light of recent FAERS-based infection data and offered clinical context for patient care.